Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Navigating the ASX dividend landscape in 2026

Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks

Meta stock has struggled amid AI spending concerns. Is it a buy?

Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks

Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth

We think Netflix stock is moderately overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,155.105.00-0.05%
CAC 408,069.176.590.08%
DAX 4024,560.98142.14-0.58%
Dow JONES (US)49,072.24583.651.20%
FTSE 10010,138.0911.310.11%
HKSE26,623.7838.720.15%
NASDAQ23,224.82270.501.18%
Nikkei 22553,784.671,010.031.91%
NZX 50 Index13,541.5732.36-0.24%
S&P 5006,873.7776.911.13%
S&P/ASX 2008,833.502.40-0.03%
SSE Composite Index4,132.6615.720.38%

Market Movers